$CNTX News

Context Therapeutics Added To Russell 2000, Russell 3000 Indexes, Effective June 26

Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4

Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study

Context Therapeutics Announces Interim Phase 1 Clinical Data For CLDN6 X CD3 T Cell Engaging Bispecific Antibody, CTIM-76, In Advanced, Late-Line Platinum-Resistant Ovarian Cancer

Context Therapeutics Q1 EPS $(0.09) Beats $(0.12) Estimate

Context Therapeutics Receives FDA's Fast Track Designation For CTIM-76 To Treat Platinum-Resistant Ovarian Cancer

Guggenheim Reiterates Buy on Context Therapeutics, Maintains $5 Price Target

Piper Sandler Maintains Overweight on Context Therapeutics, Raises Price Target to $7

Context Therapeutics Q4 EPS $(0.14) Misses $(0.10) Estimate

Context Therapeutics to Participate in Upcoming Investor Conferences

Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jones Trading Initiates Coverage On Context Therapeutics with Buy Rating, Announces Price Target of $7

BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ...

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

Context Therapeutics Showcases CT-95 And CT-202 At 2025 SITC; CT-95 Advancing In Phase 1 With Favorable Safety, Initial Data Mid-2026; CT-202 Targeting First-In-Human In Q2 2026

D. Boral Capital Maintains Buy on Context Therapeutics, Maintains $9 Price Target

HC Wainwright & Co. Maintains Buy on Context Therapeutics, Raises Price Target to $5